Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up.

Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma

Session: Real-world experience of monoclonal antibodies in asthma
Session type: Thematic Poster
Number: 2519

Disease area: Airway diseases



Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Barbetta (Pordenone, Italy), M. Conte (Pordenone, Italy), F. Zampieri (Pordenone, Italy), C. Rinaldo (Pordenone, Italy), P. Peditto (Pordenone, Italy), M. Tamburrini (Pordenone, Italy), U. Zuccon (Pordenone, Italy), A. Scarda (Pordenone, Italy), C. Baghiris (Pordenone, Italy), F. Buzzulini (Pordenone, Italy), D. Villalta (Pordenone, Italy), F. Mazza (Pordenone, Italy). Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up.. 2519

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• The Relationship Between Functional Status and Fatigue After COVID-19 Infection
• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency